Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BFH772 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| BFH772 cream 1% | EXPERIMENTAL | - |
| Placebo to BFH772 cream 1% | PLACEBO_COMPARATOR | - |
| BFH772 ointment 1% | EXPERIMENTAL | - |
| Placebo to BFH772 ointment | PLACEBO_COMPARATOR | - |
| calcipotriol/betamethasone ointment | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BFH772 | DRUG | - |
| Placebo | DRUG | - |
| calcipotriol/betamethasone | DRUG | - |
Inclusion Criteria: * Stable mild to moderate plaque psoriasis (BSA involvement \< 10% or PASI \< 10 * Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthri...
BFH772 is an investigational small molecule being developed for the treatment of psoriasis, a dermatological condition. It is currently in Phase 1 clinical development and has been studied in patients with psoriasis and arthritis.
BFH772 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development for psoriasis.
BFH772 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 15 participants with psoriasis.
BFH772 has been studied in one completed Phase 1 clinical trial, identified as NCT00987870. This trial evaluated the safety and efficacy of BFH772 in patients with psoriasis and arthritis in Germany, with an enrollment of 15 participants.
BFH772 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial, NCT00987870, was a randomized, double-blind, placebo-controlled study in patients with psoriasis and arthritis.